"I would like to thank Sheldon for his valuable contributions to the company, and, on behalf of the board, I wish him every success in his future endeavours," said Jeffrey Renwick, Canntab chief executive.
Ontario-based Canntab is developing advanced pharmaceutical-grade formulations of cannabinoids.
It has in-house technology to deliver standardized medical cannabis extract from selective strains in a variety of extended/sustained-release pharmaceutical dosages for therapeutic use.
It recently filed two additional Canadian patent applications, bolstering its intellectual property portfolio. Canntab's portfolio now includes 13 applications in Canada, the US and internationally.
Canntab is the first company to offer medical marijuana in pill form in Canada and possibly the rest of the world.